Azitra Inc is an early-stage clinical biopharmaceutical company. The Company is focused on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products that can be applied topically to treat diseases of the skin. Its platform includes a microbial library ... Azitra Inc is an early-stage clinical biopharmaceutical company. The Company is focused on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products that can be applied topically to treat diseases of the skin. Its platform includes a microbial library comprised of approximately 1,500 bacterial strains that can be screened for therapeutic characteristics. The platform is augmented by artificial intelligence and machine learning technology that analyzes, predicts and helps screen its library of strains for drug-like molecules. Its product ATR-12 is a genetically modified strain of S. epidermidis for treating the orphan disease, Netherton syndrome, a chronic and fatal disease of the skin. Its product ATR-04 is a genetically modified strain of S. epidermidis for treating the papulopustular rash. Its product ATR-01 is a human filaggrin protein for treating ichthyosis vulgaris, a chronic, xerotic (abnormally dry), and scaly skin disease. Show more
Azitra, Inc. Announces Q3 2024 Financial Results and Provides Business Updates PR Newswire BRANFORD, Conn., Nov. 12, 2024 BRANFORD, Conn., Nov. 12, 2024 /PRNewswire/ -- Azitra, Inc. (NYSE...
Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that the Company will present...
Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that the Company has been...
Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced the upcoming late-breaking...
Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced the U.S. Food and Drug...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.0541 | 11.6269073716 | 0.4653 | 0.5197 | 0.45 | 122895 | 0.48820663 | CS |
4 | 0.0294 | 6 | 0.49 | 0.6 | 0.4264 | 167341 | 0.49070403 | CS |
12 | -0.0705 | -11.9511781658 | 0.5899 | 0.667 | 0.4264 | 225603 | 0.54252816 | CS |
26 | -5.7146 | -91.6682707732 | 6.234 | 12 | 0.4264 | 2060390 | 3.2717474 | CS |
52 | -33.3806 | -98.4678466077 | 33.9 | 68.4 | 0.4264 | 1361818 | 4.28323161 | CS |
156 | -127.2806 | -99.5935837246 | 127.8 | 155.4 | 0.4264 | 942229 | 4.90873126 | CS |
260 | -127.2806 | -99.5935837246 | 127.8 | 155.4 | 0.4264 | 942229 | 4.90873126 | CS |
Symbol | Price | Vol. |
---|---|---|
AAPYKurv Yield Premium Strategy Apple AAPL ETF | $ 27.3666 (0.00%) | 0 |
AAPXT Rex 2X Long Apple Daily Target ETF | $ 34.4862 (0.00%) | 0 |
AAPRInnovator Equity Defined Protection ETF 2 Yr to April 2026 | $ 26.3969 (0.00%) | 0 |
AAAUGoldman Sachs Physical Gold ETF Shares | $ 26.07 (0.00%) | 0 |
AAAAlternative Access First Priority CLO Bond ETF | $ 25.16 (0.00%) | 0 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.